Topic summary

Molecular mass of semaglutide and why the figure differs between sources — does this still hold?

Compounds › Semaglutide effect size type 2 diabetes STEP programme SELECT trial randomised trial Solved Closed

This is a generated summary. It shows the 9 most-liked posts from a topic of 103, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

l.solbergTL2 Moderator Solution17 Dec 2024#3

h.mensah, post #2: Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.

7 likes in reply to #2 19mo

m.restrepoTL2 Moderator18 Dec 2024#6

Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

27 likes 19mo

r.nakamuraTL2 Moderator20 Dec 2024#26

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

31 likes 19mo

two_year_lineTL3Regular20 Dec 2024#32

m.steiner, post #22: The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval. Go to post

post #31 is right about the mechanism and I think understates the practical bit.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

28 likes in reply to #22 19mo

p.mwangiTL2 Moderator22 Dec 2024#58

two_year_line, post #32: post #31 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

32 likes in reply to #32 19mo

NicolaidesTL3Regular22 Dec 2024#61

j.moreau, post #24: The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Go to post

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

33 likes in reply to #24 19mo

au.pereiraTL2 Moderator23 Dec 2024#75

e.verhoeven, post #4: I read post #3 twice before replying, because I had assumed the opposite. The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of… Go to post

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

31 likes in reply to #4 19mo

eire_readerTL2Regional · IE24 Dec 2024#84

s.cardoso, post #47: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

27 likes in reply to #47 19mo

m.ibarraTL2 Moderator25 Dec 2024#102

30 likes 19mo

Read the full topic (103 posts)

This topic was closed 120 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide type 2 diabetes randomised trial semaglutide SELECT trial Solved Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…	+5	9	30k	8d
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Solved Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…		2	1.9k	5mo
Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide semaglutide effect size randomised trial type 2 diabetes Wiki Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…	+128	145	3k	4mo
Comparing the STEP programme populations: who was actually enrolled — the long version Compounds › Semaglutide STEP programme randomised trial type 2 diabetes On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with…		4	7.7k	11mo
Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016).…	+2	6	18k	17mo

Related topics — sharing the tags effect size, type 2 diabetes, STEP programme

Topic	Participants	Replies	Views	Activity
Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Compounds › Oral incretins orforglipron SOUL trial PIONEER programme randomised trial Solved Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…	+98	106	3.1k	10mo
About the N-of-1 designs category Research Methods › N-of-1 designs worked example confounding effect size Pinned Wiki Designing a personal experiment that could actually change your mind, including washouts and blinding. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…		4	22k	14h
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Compounds › Semaglutide effect size type 2 diabetes randomised trial Solved Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…	+72	77	7.2k	19mo
Criticising the method without criticising the authors — one year on Evidence › Study critique confounding effect size disputed risk of bias Solved Closed On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…	+16	20	61k	11mo
PCOS and metabolic overlap: what is and is not studied Clinical › Comorbidities chronic kidney disease MASH / hepatic steatosis obstructive sleep apnoea type 2 diabetes On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in this…		3	6.6k	1d